Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. The PLEKHA1-TACC2 fusion gene drives tumorigenesis via vascular mimicry formation in esophageal squamous-cell carcinoma.Cell death and differentiation · 2025
   Article
2. Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.Gastroenterology & hepatology · 2025
   Article
3. Sequential Use of Sorafenib and Regorafenib in Hepatocellular Cancer Recurrence After Liver Transplantation: Treatment Strategies and Outcomes.Cancers · 2024
   Article
4. Systemic Treatment in Intermediate Stage (Barcelona Clinic Liver Cancer-B) Hepatocellular Carcinoma.Cancers · 2023
   Review
5. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.Cureus · 2022
   Review
6. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.Journal of gastrointestinal oncology · 2022
   Article
7. Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study.Evidence-based complementary and alternative medicine : eCAM · 2022
   Article
8. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma.Journal of family medicine and primary care · 2021
   Review
9. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review.Pharmaceuticals (Basel, Switzerland) · 2021
   Review
10. Cabozantinib for advanced hepatocellular carcinoma.Hepatobiliary surgery and nutrition · 2019
    Article
11. Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Liver cancer · 2019
    Article
12. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.World journal of gastroenterology · 2019
    Review
13. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.Cancers · 2018
    Review
14. Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.Liver cancer · 2018
    Article
15. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.Liver cancer · 2018
    Article
16. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.Liver cancer · 2018
    Review
17. A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.Liver cancer · 2017
    Article
18. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.Liver cancer · 2017
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.